CN115537356B - Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof - Google Patents
Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN115537356B CN115537356B CN202211241806.0A CN202211241806A CN115537356B CN 115537356 B CN115537356 B CN 115537356B CN 202211241806 A CN202211241806 A CN 202211241806A CN 115537356 B CN115537356 B CN 115537356B
- Authority
- CN
- China
- Prior art keywords
- probiotic
- blood pressure
- preventing
- lactobacillus
- efficacy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 74
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 74
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 59
- 230000036772 blood pressure Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000002131 composite material Substances 0.000 title claims description 25
- 230000000694 effects Effects 0.000 claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 18
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 15
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 5
- 235000013361 beverage Nutrition 0.000 claims description 14
- 238000004321 preservation Methods 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 229940032147 starch Drugs 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 150000005846 sugar alcohols Chemical class 0.000 claims description 11
- 229920001202 Inulin Polymers 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 9
- 229940029339 inulin Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000003223 protective agent Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 5
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims description 5
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 235000013406 prebiotics Nutrition 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229920000107 Acetylated distarch adipate Polymers 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229920003012 Hydroxypropyl distarch phosphate Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 239000004383 Steviol glycoside Substances 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000001245 distarch phosphate Substances 0.000 claims description 2
- 235000013804 distarch phosphate Nutrition 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 239000001310 hydroxy propyl distarch phosphate Substances 0.000 claims description 2
- 235000013825 hydroxy propyl distarch phosphate Nutrition 0.000 claims description 2
- DVROLKBAWTYHHD-UHFFFAOYSA-N hydroxy propyl distarch phosphate Chemical compound OC1C(O)C(OC)OC(CO)C1OC(O)CCOC1C(OC2C(C(O)C(OC3C(C(OP(O)(=O)OC4C(C(O)C(OC)OC4CO)O)C(C)OC3CO)O)OC2COC2C(C(O)C(OC)C(CO)O2)O)O)OC(CO)C(OC)C1O DVROLKBAWTYHHD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- 229940080313 sodium starch Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 235000019411 steviol glycoside Nutrition 0.000 claims description 2
- 229930182488 steviol glycoside Natural products 0.000 claims description 2
- 150000008144 steviol glycosides Chemical class 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims 4
- 229940039696 lactobacillus Drugs 0.000 claims 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 description 10
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 9
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/245—Lactobacillus casei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a compound probiotic with an effect of preventing or relieving blood pressure rise, a preparation method and application thereof, wherein probiotics in the compound probiotic comprise lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain and lactobacillus helveticus Lactobacillus helveticus LH strain. The three strains are creatively compounded to obtain the compound probiotic, and the components are matched and synergistic mutually, so that the compound probiotic has more remarkable effect of relieving the rise of blood pressure compared with a single strain. The compound probiotic agent can be further applied to the preparation of foods, health products or medicines.
Description
Technical Field
The invention belongs to the technical field of probiotics, and relates to a composite probiotic with an effect of preventing or relieving blood pressure rise, and a preparation method and application thereof.
Background
Hypertension is the most common cardiovascular disease found so far, and is also the main pathogenic mechanism of diseases such as sudden cerebral death, coronary heart disease, renal failure and the like, so that the risk of cardiovascular system diseases can be reduced by preventing and treating hypertension. At present, people pay more attention to research, prevention and treatment of hypertension, and the research of multifunctional food in the aspect of reducing blood pressure has important effect. Hypertension has been shown to be caused by a variety of causes, including neurological, genetic, mental, endocrine, and Angiotensin Converting Enzyme (ACE), among others.
The mechanism of blood pressure lowering in humans is generally mediated by a group of antagonistic systems, the renin angiotensin system and the kinin-kinin regenerating enzyme system. In a human body, after kidney elements flow into plasma, carrying out a hydrolysis process on angiotensinogen in the plasma to obtain capillary tensional I (AT 1); because the function of angiotensin converting enzyme ACE converts capillary tensional I into capillary tensional II (Ang II), capillary tensional II can improve the contractility of heart and can also lead to the increase of high pressure caused by the contraction of vascular smooth muscle. At the same time, ACE has also been involved in regulating the kallikrein system, resulting in the conversion of bradykinin with bradykinin function to inactive sustained and controlled release peptides. ACE acts synergistically on both systems, causing an increase in high pressure in the human body. To achieve a drop in blood pressure, ACE activity must be inhibited.
ACE also directly activates adrenal cortex to release aldosterone, and its main action mechanism is to increase extracellular fluid capacity and human plasma volume by reducing excretion of salt and water from kidney, thereby increasing venous return current and indirectly inducing hypertension. The protease produced by lactobacillus plantarum shears part of the activity fragments and simultaneously releases the activity fragments, the part of the activity fragments are fused with the activity center of ACE, the ACE activity is competitively controlled, and the angiotensin I can not be converted into angiotensin II, so that the purpose of reducing blood pressure is realized.
The primary antihypertensive drugs proposed at present are five major classes of beta receptor blockers, diuretics, capillary tensioners invertase inhibitors (ACEI), calcium channel blockers, capillary tensioners ii two-receptor binding inhibitors. Each medicine has the characteristics and certain side effects.
ACEI has certain curative effect on patients with hypertension in various periods, does not cause heart rate increase or interfere with the regulation of vascular smooth muscle by parasympathetic nervous system, but the synthesized ACEI has main adverse effects of easily generating proteinuria, rash, leucopenia and the like. Treatment with antihypertensive drugs is responsible for increased incidence of coronary heart disease; changes in metabolism during drug therapy can be affected, particularly potentially detrimental effects on glucose, fat and uric acid metabolism; the probability of cerebral blood reduction caused by the blood pressure reduction caused by the drug treatment is increased, and vision disorder, cerebral ischemia, ischemic cerebral apoplexy and the like can be caused. Thus, there is increasing interest in treating hypertension by non-drug therapy.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a compound probiotic with the efficacy of preventing or relieving the rise of blood pressure, and a preparation method and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the invention provides a composite probiotic with the effect of preventing or alleviating elevated blood pressure, wherein probiotics in the composite probiotic comprise lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain 89 and lactobacillus helveticus Lactobacillus helveticus LH strain 76.
The invention creatively compounds three strains of lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain and lactobacillus helveticus Lactobacillus helveticus LH strain to obtain the compound probiotic, and all the components are matched and synergistic mutually.
Preferably, the ratio of the viable count of the lactobacillus plantarum Lactobacillus plantarum Lp strain, the lactobacillus casei Lactobacillus casei LC strain and the lactobacillus helveticus Lactobacillus helveticus LH strain is (10-20): 5-10): 15-30.
The specific point values in (10-20) may be selected from 10, 12, 14, 15, 16, 17, 18, 20, etc.
The specific point values in (5-10) may be selected from 5, 6, 7, 8, 9, 10, etc.
The specific point values in (15-30) may be selected from 15, 17, 18, 20, 22, 25, 28, 30, etc.
Other specific point values in the numerical ranges are selectable, and will not be described in detail herein.
Preferably, the composite probiotic agent further comprises a protective agent.
Preferably, the protective agent comprises skim milk and/or skim milk powder.
Preferably, the composite probiotic agent further comprises a carrier.
Preferably, the carrier comprises any one or a combination of at least two of microcrystalline cellulose, inulin, magnesium stearate, sugar alcohols or starch.
Preferably, the carrier is a combination of microcrystalline cellulose, sugar alcohol, inulin and starch.
The combination of microcrystalline cellulose, sugar alcohol, inulin and starch is more preferred for the carrier because in this combination the complex probiotic is more stable and can maintain the product morphology and mouthfeel for a long period of time.
Preferably, the sugar alcohol is selected from any one or a combination of at least two of xylitol, maltitol, erythritol, sorbitol, isomalt or lactitol.
Preferably, the starch is selected from any one or a combination of at least two of acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate or acetylated distarch adipate.
The formulation of the composite probiotics can be freeze-dried powder, tablets, capsules, solutions, emulsions and the like.
In a second aspect, the present invention provides a method for preparing the composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to the first aspect, the method comprising:
(1) Mixing lactobacillus plantarum Lactobacillus plantarum Lp, lactobacillus casei Lactobacillus casei LC and lactobacillus helveticus Lactobacillus helveticus LH76 with a protective agent according to a proportion to obtain an emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier, and performing micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic with the effect of preventing or relieving the rise of blood pressure.
In a third aspect, the present invention provides the use of a complex probiotic with efficacy in preventing or alleviating elevated blood pressure according to the first aspect in the manufacture of a medicament.
In a fourth aspect, the invention provides a probiotic beverage, which is prepared from the following raw materials in percentage by mass: the compound probiotics of the first aspect are 0.01-10%, prebiotics 0.01-5%, stabilizing agent 0.1-1%, sweetener 0.01-0.05% and water.
The mass percentage of the composite probiotics can be selected from 0.01%, 0.1%, 1%, 2%, 3%, 5%, 7%, 8%, 10% and the like.
The mass percentage of the prebiotics can be selected from 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 3.5%, 4%, 5% and the like.
The mass percentage of the stabilizer can be selected from 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 1% and the like.
The mass percentage of the sweetener can be selected from 0.01%, 0.02%, 0.03%, 0.04%, 0.05% and the like.
Other specific point values in the numerical ranges are selectable, and will not be described in detail herein.
Preferably, the prebiotic is selected from any one or a combination of at least two of stachyose, fructo-oligosaccharide, isomaltooligosaccharide or galactooligosaccharide.
Preferably, the sweetener is selected from any one or a combination of at least two of acesulfame potassium, aspartame, sucralose or steviol glycosides.
Preferably, the stabilizer is selected from any one or a combination of at least two of sodium carboxymethyl cellulose, pectin, soybean polysaccharide, agar or sodium caseinate; preferably a combination of pectin and soy polysaccharide.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively compounds three strains of lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain and lactobacillus helveticus Lactobacillus helveticus LH strain to obtain the compound probiotic, and all the components are matched and synergistic mutually.
Detailed Description
In order to further describe the technical means adopted by the present invention and the effects thereof, the following describes the technical scheme of the present invention in combination with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
(1) The lactobacillus plantarum Lp05 is lactobacillus plantarum Lactobacillus plantarum Lp strain, the preservation unit is China general microbiological culture Collection center, the preservation number is CGMCC No.23547, the preservation date is 2021 and 10 and 09 days, and the preservation address is North Chen and West road No.1 and 3 in the Korean region of Beijing city.
(2) The lactobacillus helveticus LH76 is lactobacillus helveticus Lactobacillus helveticus LH strain, the preservation unit is China general microbiological culture Collection center (CGMCC) No.18796, the preservation date is 2019, 11 months and 4 days, and the preservation address is North Chen Xili No.1, 3 in the Korean region of Beijing city.
(3) The lactobacillus casei LC89 is lactobacillus casei Lactobacillus casei LC strain, the preservation unit is China general microbiological culture Collection center, the preservation number is CGMCC No.15409, the preservation date is 2018, 03 and 05, and the preservation address is North Chen West Lu No.1 of the Korean region of Beijing city.
MRS solid medium as described below: weighing peptone 10g, beef extract 10g, glucose 20 g, lactose 10g, yeast extract 5 g, diammonium hydrogen citrate 2 g, K 2 PO 4 ·3H 2 O 2 g、MgSO 4 ·7H 2 O 0.6 g、MnSO 4 0.01 g, agar 20 g and L-cysteine 1 g, dissolving with deionized water, adding 1 mL Tween 80, fixing volume to 1L, sterilizing, cooling, and pouring into sterilized culture dish.
MRS liquid medium is as follows: weighing peptone 10g, beef extract 10g, glucose 20 g, lactose 10g, yeast extract 5 g, diammonium hydrogen citrate 2 g, K 2 PO 4 ·3H 2 O 2 g、MgSO 4 ·7H 2 O 0.6 g、MnSO 4 0.01 g and L-cysteine 1 g are dissolved by deionized water, then 1 mL Tween 80 is added, the volume is fixed to 1L, and after sterilization and cooling, the mixture is poured into a sterilized culture dish for standby.
The following lactobacillus plantarum Lp05, lactobacillus helveticus LH76, lactobacillus casei LC89 bacterial suspensions are involved: inoculating the bacteria into MRS liquid culture medium, culturing at 38deg.C for 18h for activation, and continuously activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 38deg.C for 18h to obtain bacterial solution; centrifuging the bacterial liquid at 8000g for 10min, collecting supernatant, and filtering with 0.22 μm sterile filter membrane to obtain supernatant; and (5) re-suspending the thalli by using PBS to obtain the microbial inoculum.
The sources of the components in the following examples are shown below:
example 1
This example demonstrates gastric acid resistance of three bacteria, as follows:
(1) Preparing artificial gastric juice:
the artificial gastric juice contains 0.20% of NaCl and 0.30% of pepsin by mass fraction, the pH is regulated to 3.0 by using HCl, and the artificial gastric juice is filtered for sterilization for standby.
(2) Gastric acid resistance test:
taking 1.0 mL Lactobacillus plantarum Lp05, lactobacillus helveticus LH76 and Lactobacillus casei LC89 suspension (1×10 concentration) 9 CFU/mL, the concentration of bacterial liquid is measured by the method in national standard food safety national Standard microbiological detection of lactic acid bacteria of GB4789.35-2016, respectively, and is mixed with 9.0 mL of artificial gastric juice with pH of 3.0, and then anaerobic stationary culture is carried out at 37 ℃, sampling is carried out after 0h and 3h treatment are started, the viable count is measured by a pouring culture method, and the survival rate is calculated, wherein the formula is as follows:
survival (%) =n1/n0×100%,
wherein, N1: viable count after 3 hours of artificial gastric juice treatment; n0: viable count of 0 h. The test results are shown in Table 1.
TABLE 1
As can be seen from the data in table 1: the probiotics disclosed by the invention have good gastric acid resistance and good acid resistance, and conditions are created for preparing products for preventing or relieving hypertension from rising.
Example 2
The example demonstrates the bile salt resistance of three bacteria, the steps being as follows:
the bacterial liquid content is adjusted to 10 8 centrifuging cfu/ml at 3000r/min for 10min, removing supernatant, adding sterilized MRS liquid culture medium containing 0.3% bile salt to the centrifuged thallus, shaking uniformly, placing into a constant temperature incubator at 37 deg.C, continuously taking samples within 0h and 3h, diluting with sterilized PBS, coating on MRS plate, culturing at 37 deg.C for 36h, and counting. The formula is as follows:
survival (%) =n1/n0×100%,
wherein, N1: viable count after 3 hours of treatment; n0: viable count of 0 h. The test results are shown in Table 2.
TABLE 2
As can be seen from the data in table 2: the probiotics provided by the invention have good bile salt resistance, and good bile salt resistance creates conditions for preparing products for preventing or relieving hypertension.
Example 3
The embodiment provides a compound probiotic with the effect of preventing or relieving the rise of blood pressure, and the preparation method comprises the following steps:
(1) Mixing 40 parts of bacterial powder (the viable count of lactobacillus plantarum Lactobacillus plantarum Lp, lactobacillus casei Lactobacillus casei LC89 and lactobacillus helveticus Lactobacillus helveticus LH76 is 15:5:20) with 10 parts of skim milk to obtain emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier (5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, 10 parts of inulin and 10 parts of starch), and performing micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic with the effect of preventing or relieving the rise of blood pressure.
Example 4
The preparation method of the compound probiotic with the effect of preventing or relieving the rise of blood pressure is different from that of the embodiment 3 only in that 40 parts of bacterial powder is lactobacillus plantarum Lactobacillus plantarum Lp05 and lactobacillus casei Lactobacillus casei LC89 with the viable count of 15:5. The other steps remain unchanged.
Example 5
The preparation method of the compound probiotic with the effect of preventing or relieving the rise of blood pressure is different from that of the embodiment 3 only in that 40 parts of bacterial powder is lactobacillus plantarum Lactobacillus plantarum Lp05 and lactobacillus helveticus Lactobacillus helveticus LH with the viable count of 15:20. The other steps remain unchanged.
Example 6
The preparation method of the compound probiotic with the effect of preventing or relieving the rise of blood pressure is different from that of the embodiment 3 only in that 40 parts of bacterial powder is lactobacillus casei Lactobacillus casei LC89 and lactobacillus helveticus Lactobacillus helveticus LH with the viable count of 5:20. The other steps remain unchanged.
Example 7
The present example provides a compound probiotic with efficacy of preventing or alleviating the rise of blood pressure, and the preparation method differs from example 3 only in that the carrier in step (2) is 10 parts of sugar alcohol, 10 parts of inulin and 10 parts of starch. The other steps remain unchanged.
Example 8
The present embodiment provides a compound probiotic with an effect of preventing or alleviating an increase in blood pressure, and the preparation method is different from embodiment 3 only in that the carrier in step (2) is 10 parts of microcrystalline cellulose, 10 parts of inulin and 10 parts of starch. The other steps remain unchanged.
Example 9
The present embodiment provides a compound probiotic with an effect of preventing or alleviating an increase in blood pressure, and the preparation method is different from embodiment 3 only in that the carrier in step (2) is 5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, and 20 parts of starch. The other steps remain unchanged.
Example 10
The present embodiment provides a compound probiotic with an effect of preventing or alleviating an increase in blood pressure, and the preparation method is different from embodiment 3 only in that the carrier in step (2) is 5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, and 20 parts of inulin. The other steps remain unchanged.
Test example 1
And (3) measuring the antihypertensive effect of the composite probiotics:
(1) Experimental animals: male essential Severe Hypertension Rats (SHR), about eight weeks old, average weight 170-210 g, supplied by Shanghai laboratory animal management center, proc, animal eligibility number: shanghai Hui He pattern 152. Male SD rats, 8 weeks old, weighing 170-210 g, supplied by the experimental mammalian management center in Shanghai, national academy of sciences, animals meeting qualification number: shanghai Hui He pattern 152. The indoor illumination of animals is 12h illumination, the indoor ventilation and air conditioning equipment is normal, the room temperature is controlled at 22+/-3 ℃, and the relative humidity is about 50-70%.
(2) The experimental animals are adapted to the environment for 7 days, and after the blood pressure is stabilized, continuous gastric lavage is started, and the experimental gastric lavage time is 9:00 am every day. 40 SHR rats were randomly divided into 5 groups: model control, example 3, example 4, example 5, example 6; 8 SD rats were used as SD control group. Comparative group is filled with normal saline, and example group is filled with 10 mg/kg of the composite probiotics prepared in each example.
(3) The rats were tested after stable depressurization and pressure test, the pre-dosing depressurization and then the intragastric administration treatment were measured for the rats, the intragastric administration treatment was performed once daily for 4 weeks, the high pressure of the SHR tail artery was measured with a BP-98A intelligent noninvasive sphygmomanometer and repeated three times, the average value was obtained, and the measured value was displayed as the average value. As shown in table 3.
TABLE 3 Table 3
From the data results in table 3, it can be seen that: the composite probiotics related by the invention has remarkable effect of relieving the rise of blood pressure, and the lactobacillus plantarum Lp05 strain, the lactobacillus casei LC89 strain and the lactobacillus helveticus LH76 strain in the composite probiotics have synergistic effect on the effects.
Application example 1
The application example provides a probiotic beverage, wherein the preparation raw materials of the probiotic beverage comprise the following components in percentage by mass: 5% of the compound probiotics prepared in the embodiment 3, 5% of fructo-oligosaccharide, 0.5% of pectin, 0.5% of soybean polysaccharide, 0.04% of sucralose and the balance of water.
Application examples 2 to 8
The application example provides seven probiotic beverages, and the preparation raw materials of the probiotic beverages are different from the application example 1 only in that the compound probiotic prepared in the example 3 is replaced by the compound probiotic prepared in the examples 4-10 with equal amount respectively, and other raw materials and contents are kept unchanged.
Test example 2
Testing the stability of the probiotic beverage:
the probiotic beverages of application examples 1-8 were stored refrigerated at 4 ℃ for 21 days and the tissue state was visually observed. The products of each group are scored, the layering phenomenon is obvious in 1 division, the layering phenomenon is not obvious in 2 division, and the layering phenomenon is not obvious in 3 division, so that the products are very uniform. The results are shown in Table 4.
TABLE 4 Table 4
From the results in Table 4, it can be seen that: the beverage product prepared by using the composite probiotic provided by the invention has good stability, wherein the composition mode of the carrier material in the composite probiotic obviously influences the stability of the beverage product.
The applicant states that the present invention is described by the above examples as a composite probiotic agent having an effect of preventing or alleviating an increase in blood pressure, and a preparation method and application thereof, but the present invention is not limited to the above examples, i.e., it does not mean that the present invention must be practiced depending on the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (16)
1. A compound probiotic with the effect of preventing or relieving the rise of blood pressure is characterized in that probiotics in the compound probiotic are prepared from lactobacillus plantarum with the preservation number of CGMCC No.23547Lactobacillus plantarum) Lp05 strain and lactobacillus casei with preservation number of CGMCC No.15409Lactobacillus casei) LC89 strain and Lactobacillus helveticus with preservation number of CGMCC No.18796Lactobacillus helveticus) LH76 strain.
2. The compound probiotic with the efficacy of preventing or relieving the elevation of blood pressure according to claim 1, wherein the lactobacillus plantarum Lactobacillus plantarum Lp05 Strain, lactobacillus caseiLactobacillus caseiLC89 strain and lactobacillus helveticusLactobacillus helveticus The ratio of the viable count of LH76 strain is (10-20): 5-10): 15-30.
3. The complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 1 or 2, characterized in that the complex probiotic further comprises a protective agent.
4. A complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 3, characterized in that the protective agent comprises skim milk and/or skim milk powder.
5. The composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 1, further comprising a carrier.
6. The composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 5, wherein the carrier comprises any one or a combination of at least two of microcrystalline cellulose, inulin, magnesium stearate, sugar alcohol or starch.
7. The complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 6, wherein the carrier is a combination of microcrystalline cellulose, sugar alcohol, inulin and starch.
8. The complex probiotics for preventing or alleviating elevated blood pressure according to claim 7, wherein said sugar alcohol is selected from any one or a combination of at least two of xylitol, maltitol, erythritol, sorbitol, isomalt or lactitol.
9. The composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 7, wherein the starch is selected from any one or a combination of at least two of acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate or acetylated distarch adipate.
10. The method for producing a composite probiotic having an efficacy of preventing or alleviating an increase in blood pressure according to any one of claims 1 to 9, characterized by comprising:
(1) Lactobacillus plantarum is preparedLactobacillus plantarum Lp05, lactobacillus caseiLactobacillus caseiLC89 and Lactobacillus helveticusLactobacillus helveticus LH76 is mixed with a protective agent according to a proportion to obtain emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier, and performing micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic with the effect of preventing or relieving the rise of blood pressure.
11. Use of a complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to any one of claims 1 to 9 in the manufacture of a medicament with efficacy of preventing or alleviating elevated blood pressure.
12. The probiotic beverage is characterized by comprising the following preparation raw materials in percentage by mass: the composite probiotic of any one of claims 1-9, 0.01-10%, prebiotics 0.01-5%, stabilizers 0.1-1%, sweeteners 0.01-0.05%, water.
13. The probiotic beverage according to claim 12, characterized in that the prebiotic is selected from any one or a combination of at least two of stachyose, fructo-oligosaccharides, isomaltooligosaccharides or galactooligosaccharides.
14. The probiotic beverage according to claim 12, characterized in that the sweetener is selected from any one or a combination of at least two of acesulfame k, aspartame, sucralose or steviol glycosides.
15. The probiotic beverage according to claim 12, characterized in that the stabilizer is selected from any one or a combination of at least two of sodium carboxymethyl cellulose, pectin, soy polysaccharide, agar or sodium caseinate.
16. The probiotic beverage according to claim 15, characterized in that the stabilizer is a combination of pectin and soy polysaccharide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211241806.0A CN115537356B (en) | 2022-10-11 | 2022-10-11 | Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211241806.0A CN115537356B (en) | 2022-10-11 | 2022-10-11 | Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115537356A CN115537356A (en) | 2022-12-30 |
CN115537356B true CN115537356B (en) | 2024-02-13 |
Family
ID=84733433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211241806.0A Active CN115537356B (en) | 2022-10-11 | 2022-10-11 | Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115537356B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116515684B (en) * | 2023-03-29 | 2024-03-01 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for improving hyperphosphatemia and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050269A (en) * | 2006-08-22 | 2008-03-06 | Gekkeikan Sake Co Ltd | Oral ingestion material |
CN110179120A (en) * | 2018-02-22 | 2019-08-30 | 杨涵 | A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia |
CN113755357A (en) * | 2020-06-04 | 2021-12-07 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus preparation and application thereof |
CN114651984A (en) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113430133B (en) * | 2021-06-24 | 2023-06-23 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
CN113980878B (en) * | 2021-12-29 | 2022-03-15 | 微康益生菌(苏州)股份有限公司 | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof |
CN114854643B (en) * | 2022-06-02 | 2023-01-31 | 微康益生菌(苏州)股份有限公司 | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof |
-
2022
- 2022-10-11 CN CN202211241806.0A patent/CN115537356B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050269A (en) * | 2006-08-22 | 2008-03-06 | Gekkeikan Sake Co Ltd | Oral ingestion material |
CN110179120A (en) * | 2018-02-22 | 2019-08-30 | 杨涵 | A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia |
CN113755357A (en) * | 2020-06-04 | 2021-12-07 | 内蒙古伊利实业集团股份有限公司 | Lactobacillus preparation and application thereof |
CN114651984A (en) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation |
Also Published As
Publication number | Publication date |
---|---|
CN115537356A (en) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11268064B2 (en) | Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
CN103648512B (en) | The bacterium bacterial strain for belonging to Bifidobacterium for the treatment of hypercholesterolemia | |
CN115537356B (en) | Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof | |
CN112370470A (en) | Microecological preparation for reconstructing intestinal microecology | |
CN117106679B (en) | Probiotic agent for relieving insulin resistance and application thereof | |
CN102429034A (en) | Composite colostrum | |
AU2005247084A1 (en) | Oral and/or topical compositions comprising prebiotics and sterols | |
EP3677273B1 (en) | Bacteroides cellulosityticus for use in preventing and/or treating atherosclerosis and obesity | |
ES2357408T3 (en) | SYMBOLIC COMPOSITION AND ITS MANUFACTURING PROCEDURE. | |
JP6261688B2 (en) | QOL improvement or persistence agent | |
JP6072516B2 (en) | Allergy improving agent | |
CN107158225A (en) | A kind of Shengmai Yin composition and its preparation method and application | |
KR20040037011A (en) | Food Composition Containing a Lactic Acid Bacteria | |
EP3677272B1 (en) | Application of alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases | |
CN116270757A (en) | Use of bacillus coagulans BC99 for preventing osteoporosis and improving bone health | |
WO2006000137A1 (en) | Oral disintegrable tablet of notogingseng total sapoin and the preparation process thereof | |
CN104382002A (en) | Maca tablet for alleviating fatigue | |
CN116211956A (en) | Composition for regulating intestinal tract and/or improving obesity, preparation method, chewable tablet and application thereof | |
CN115226773A (en) | Composite probiotic sleep-aiding solid beverage and preparation method thereof | |
EP3721889A1 (en) | Use ofbutyribacter intestini | |
WO2019035486A1 (en) | Agent for suppressing spikes in blood glucose levels, method for producing food and agent for suppressing spikes in blood glucose level | |
WO2004113509A1 (en) | Lactobacillus casei lc2w strain and its use in antihypertensive aspect | |
CN113558238A (en) | Natto freeze-dried powder spina date seed solid beverage and preparation method thereof | |
CN112753775A (en) | Anti-inflammation milk powder and preparation method thereof | |
CN108685981A (en) | A kind of notoginseng-red sage capsule and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |